Head of R&D Peter Edman to leave Sobi
(Thomson Reuters ONE) -
Peter Edman, Head of R&D, will leave Sobi as of December 31, 2011.
"The years in Sobi have been exciting and rewarding", says Peter Edman. "During
this time we have restructured and focused the research operations on
recombinant protein projects within rare diseases, and taken the decision to
advance three development projects into phase III. I have the greatest respect
for the knowledge and competence within Sobi and it was not an easy decision to
leave."
"I want to thank Peter for his contributions to Sobi and we wish him well in his
future endeavors" says Geoffrey McDonough, President and CEO of Sobi. "We remain
committed to delivering our phase III and early stage development pipeline. We
will also utilize our unique competences in protein biochemistry and biologics
manufacturing to acquire new late stage assets in the rare disease area. We will
now start the process to bring in a senior individual with the appropriate
skills to build on this foundation for the future."
For additional information, please contact:
Åsa Stenqvist, Head of Communications and Investor Relations
Tel.: +46 8 697 21 88
About Swedish Orphan Biovitrum (Sobi)
Sobi is a leading European specialty pharmaceutical company focused on providing
and developing pharmaceuticals for patients with rare diseases and significant
medical needs. The portfolio comprises about 60 marketed products, as well as
projects in late clinical phase. Key therapeutic areas are hematological
diseases, autoimmune diseases, hereditary metabolic disorders and therapeutic
oncology. In 2010 Sobi had revenues of SEK 1.9 billion and approximately 500
employees. The share (STO: SOBI) is listed on NASDAQ OMX Stockholm. For more
information please visitwww.sobi.com
The above information has been made public in accordance with the Swedish
Securities Market Act and/or the Financial Instruments Trading Act. The
information was released for public distribution on October 4, 2011 at 8.30 CET.
Sobi press release October 4, 2011 in pdf version:
http://hugin.info/134557/R/1551789/478020.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Swedish Orphan Biovitrum AB (publ) via Thomson Reuters ONE
[HUG#1551789]
Unternehmensinformation / Kurzprofil:
Datum: 04.10.2011 - 08:30 Uhr
Sprache: Deutsch
News-ID 72750
Anzahl Zeichen: 2898
contact information:
Town:
Stockholm
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 166 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Head of R&D Peter Edman to leave Sobi"
steht unter der journalistisch-redaktionellen Verantwortung von
Swedish Orphan Biovitrum AB (publ) (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
